Fig. 5: Plasma AOPP and B-ALP concentrations in each group.

A The intraperitoneal injection of AOPPs daily for 16 weeks markedly increased the plasma AOPP level, while rapamycin intervention significantly inhibited this trend. B The intraperitoneal injection of AOPPs daily for 16 weeks markedly decreased the plasma B-ALP level, while rapamycin intervention significantly inhibited this trend. Data are presented as the mean ± SD, *P < 0.05 versus control, #P < 0.05 versus AOPPs, n = 8.